No mention of Head & Neck cancer HPV etc in the above article re translate bio...
3) Our HPV and RNA projects are a different situation to the HSV study and thus moving on a separate course. We do have a collaboration agreement with a third-party company originating with Shire pharmaceuticals that I was set to announce when Shire sold this division to a Boston-based company (and this has caused delays outside of our control). The company that purchased the RNA assets from Shire (Translate Bio) is undergoing their own review of all of their assets (not just the AHZ ones) and we are stuck until I get further feedback from them on next steps. I am bullish on the RNA assets, particularly in the oncology arena (head and neck cancer combination with a check point inhibitor).
- Forums
- ASX - By Stock
- AVR
- Immunotherapy Partner Patrick Soon Shiong
Immunotherapy Partner Patrick Soon Shiong, page-25
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$18.60 |
Change
-0.100(0.53%) |
Mkt cap ! $357.5M |
Open | High | Low | Value | Volume |
$18.70 | $18.77 | $18.21 | $664.1K | 35.88K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | $18.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.69 | 53 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 18.400 |
1 | 1000 | 16.000 |
1 | 198 | 15.150 |
1 | 1000 | 14.950 |
1 | 219 | 13.670 |
Price($) | Vol. | No. |
---|---|---|
18.690 | 53 | 1 |
18.800 | 258 | 1 |
18.900 | 500 | 1 |
18.910 | 100 | 1 |
19.500 | 21 | 1 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online